The oncolytic immunotherapy drug cretostimogene grenadenorepvec has demonstrated groundbreaking results for the treatment of high-risk (HR) Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) based on new topline data from the phase III BOND-003 trial. CG Oncology has reported that 82 of 110 patients (74.5%) involved in the trial met the primary endpoint of complete response at any time after receiving single agent cretostimogene. At 12 months, 97.3% of patients were free from progression to MIBC. At 12 and 24 months or greater, a total of 63.5% and 56.6% of patients remained in response, ...
Urothelial Carcinoma
Advertisement
Latest News
Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1. 
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Radical prostatectomy with pelvic lymph node dissection increases risks of complications like DVT and lymphatic leaks.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1. 
Patient-derived organoids show promise in RCC, enabling personalized therapies and resistance insights.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
The phase 3 trial evaluates combination mevrometostat in patients with mCRPC previously treated with abiraterone acetate.
Advertisement
Advertisement
Latest News
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.